ABSTRACT
Modern radiotherapy applications such as dose staining and intensity-modulated radiotherapy require diagnostic images that can offer good resolution and high soft tissue contrast. The combination of positron emission tomography (PET) and magnetic resonance (MR) in the same imaging session can improve tumor target volume identification, as well as reduce tumor and organ movements of the patient with different scanning times. Hybrid PET/MR imaging is gaining increasing attention in radiotherapy planning, adaptive radiotherapy applications and treatment response evaluation. Single-center studies limited to academic centers and based on small sample sizes are due to the relatively low availability of hybrid PET/MR imaging devices due to their high costs.
References
1
Zhu T, Das S, Wong TZ. Integration of PET/MR Hybrid Imaging into Radiation Therapy Treatment. Magn Reson Imaging Clin N Am 2017;25:377-430.
2
Hirsch FW, Sattler B, Sorge I, et al. PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner. Pediatr Radiol 2013;43:860-875.
3
O’Connor LM, Dowling JA, Choi JH, et al. Validation of an MRI-only planning workflow for definitive pelvic radiotherapy. Radiat Oncol 2022;17:55.
4
Paulus DH, Oehmigen M, Grüneisen J, Umutlu L, Quick HH. Whole-body hybrid imaging concept for the integration of PET/MR into radiation therapy treatment planning. Phys Med Biol 2016;61:3504-3520.
5
Brynolfsson P, Axelsson J, Holmberg A, et al. Technical Note: Adapting a GE SIGNA PET/MR scanner for radiotherapy. Med Phys 2018.
6
Ahangari S, Hansen NL, Olin AB, et al. Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients. Acta Oncol 2021;60:1045-1053.
7
Leibfarth S, Mönnich D, Welz S, et al. A strategy for multimodal deformable image registration to integrate PET/MR into radiotherapy treatment planning. Acta Oncol 2013;52:1353-1359.
8
Fortunati V, Verhaart RF, Angeloni F, et al. Feasibility of multimodal deformable registration for head and neck tumor treatment planning. Int J Radiat Oncol Biol Phys 2014;90:85-93.
9
Iğdem S, Alço G, Ercan T, et al. The application of positron emission tomography/computed tomography in radiation treatment planning: effect on gross target volume definition and treatment management. Clin Oncol (R Coll Radiol) 2010;22:173-178.
10
Deantonio L, Castronovo F, Paone G, Treglia G, Zilli T. Metabolic Imaging for Radiation Therapy Treatment Planning: The Role of Hybrid PET/MR Imaging. Magn Reson Imaging Clin N Am 2023;31:637-654.
11
Decazes P, Hinault P, Veresezan O, Thureau S, Gouel P, Vera P. Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review. Front Oncol 2021;10:614008.
12
Seifert R, Kersting D, Rischpler C, et al. Clinical Use of PET/MR in Oncology: An Update. Semin Nucl Med 2022;52:356-364.
13
Morsing A, Hildebrandt MG, Vilstrup MH, et al. Hybrid PET/MRI in major cancers: a scoping review. Eur J Nucl Med Mol Imaging 2019;46:2138-2151.
14
Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
15
Becker M, Varoquaux AD, Combescure C, et al. Local recurrence of squamous cell carcinoma of the head and neck after radio(chemo)therapy: Diagnostic performance of FDG-PET/MRI with diffusion-weighted sequences. Eur Radiol 2018;28:651-663.
16
Chan SC, Yeh CH, Yen TC, et al. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1297-1308.
17
Terzidis E, Friborg J, Vogelius IR, et al. Tumor volume definitions in head and neck squamous cell carcinoma- Comparing PET/MRI and histopathology. Radiother Oncol 2023;180:109484.
18
Cao C, Xu Y, Huang S, et al. Locoregional extension patterns of nasopharyngeal carcinoma detected by FDG PET/MR. Front Oncol 2021;11:763114.
19
Lopez WOC, Cordeiro JG, Albicker U, et al. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool. Onco Targets Ther 2015;8:3803-3815.
20
Song S, Cheng Y, Ma J, et al. Simultaneous FET-PET and contrast-enhanced MRI based on hybrid PET/MR improves delineation of tumor spatial biodistribution in gliomas: a biopsy validation study. Eur J Nucl Med Mol Imaging 2020;47:1458-1467.
21
Lohmann P, Lerche C, Bauer EK, et al. Predicting IDH genotype in gliomas using FET PET radiomics. Sci Rep 2018;8:13328.
22
Haubold J, Demircioglu A, Gratz M, et al. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting. Eur J Nucl Med Mol Imaging 2020;47:1435-1445.
23
Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2019;30:1194-1220.
24
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31:1623-1649.
25
Cardoso F, Senkus E, Costa A, et al. 4th ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 4)y. Ann Oncol 2018;29:1634-1657.
26
Pujara AC, Kim E, Axelrod D, Melsaether AN. PET/MRI in Breast Cancer. J Magn Reson Imaging. 2019;49:328-342.
27
Ming Y, Wu N, Qian T, et al. Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer. Front Oncol 2020;10:1301.
28
Çelebi F, Köksal Ü, Pilancı KN, et al. PET-MRI Findings of Two Patients with Breast Carcinoma before Treatment. J Breast Health. 2016;12:88-90.
29
Stabile A, Giganti F, Rosenkrantz AB, et al. Multiparametric MRI for prostate cancer diagnosis: Current status and future directions. Nat Rev Urol 2020;17:41-61.
30
Eiber M, Herrmann K, Calais J, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 2018;59:469-478.
31
Emmett L, Buteau J, Papa N, et al. The additive diagnostic value of prostate- specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): A prospective multicentre study. Eur Urol 2021;80:682-689.
32
Zhang S, Xin J, Guo Q, et al. Defining PET tumor volume in cervical cancer with hybrid PET/MRI: a comparative study. Nucl Med Commun 2014;35:712-719.
33
Scharl S, Weidenbaecher CB, Hugo C, et al. First experiences with PET-MRI/CT in radiotherapy planning for cervical cancer. Arch Gynecol Obstet 2022;306:1821-1828.
34
Zhang YN, Lu X, Lu ZG, Fu LP, Zhao J, Xiang ZL. Evaluation of hybrid PET/MRI for gross tumor volume (GTV) delineation in colorectal cancer liver metastases radiotherapy. Cancer Manag Res 2021;13:5383-5389.
35
Delaby G, Ataeinia B, Wo J, Catalano OA, Heidari P. Impact of 18F-FDG PET/MR based tumor delineation in radiotherapy planning for cholangiocarcinoma. Abdom Radiol (NY) 2021;46:3908-3916.
36
Crimì F, Spolverato G, Lacognata C, et al. 18F-FDG PET/MRI for rectal cancer TNM restaging after preoperative chemoradiotherapy: Initial experience. Dis Colon Rectum 2020;63:310-318.
37
Capelli G, Campi C, Bao QR, et al. 18F-FDG-PET/ MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy. Nucl Med Commun 2022;43:815-822.
38
Kessler L, Ferdinandus J, Hirmas N, et al. Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial. J Nucl Med 2020;63:89-95.
39
Prakken NHJ, Besson FL, Borra RJH, et al. PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL). Eur J Nucl Med Mol Imaging 2023;50:2927-2934.